Am J Perinatol. 2022 Apr 18. doi: 10.1055/a-1827-7518. Online ahead of print.
ABSTRACT
Objective To evaluate the utility of brain natriuretic peptide (BNP), troponin, galectin-3 and miRNA-126a-5p as screening biomarkers for persistent pulmonary hypertension of the newborn (PPHN) by comparing expression in serum of infants with hypoxic-ischemic injury that develop PPHN to those that do not. Study design This was a prospective, observational pilot study including neonates with hypoxic-ischemic injury undergoing therapeutic hypothermia (TH) at two regional perinatal medical centers. PPHN in this population was diagnosed clinically and confirmed by ECHO. Serial measurements of biomarkers were performed from 6-96 hours post-TH initiation in 40 patients. Results Of 40 infants in study, 10 (25%) developed PPHN and 30 (75%) did not. Baseline demographics and hemodynamics were similar between the groups. Patients with PPHN had significantly higher need for vasopressors compared to patients without PPHN (70% vs. 27%, p=0.007). Mean serum BNP and troponin levels were significantly higher in PPHN group peaking at 12-24 hours and decreasing following PPHN treatment initiation. MiRNA-126a-5p expression was increased in patients with PPHN compared to patients without, with statistical significance detected at 12 hours (p=0.005) and 96 hours (p=0.01). Mean circulating Gal-3 levels were not statistically different between the two groups; however, Gal-3 was elevated in all patients with hypoxic-ischemic injury on TH compared to healthy infants from prior studies. Conclusion BNP and troponin are readily available, low-cost biomarkers that showed significant serial elevations in PPHN group of study, thus may have value in screening for PPHN in the setting of HIE. Galectin-3 was elevated in all patients with HIE and may be a useful biomarker of hypoxic injury in infants being evaluated for TH. Elevations in MiRNA-126a-5p were not consistently seen in this study. Larger studies are required to establish an association between PPHN and these biomarkers in patients with and without HIE.
PMID:35436801 | DOI:10.1055/a-1827-7518